{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiducpg257zw4ry7tbgmm34w4glu3vn44cvybuxjsahizqd7kfx26e",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mm7qqi52ux22"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicralgl7w4s3mmkl5npqso5ceqjlf53c3vn7wo77chhwi5edp7dvi"
    },
    "mimeType": "image/jpeg",
    "size": 350967
  },
  "path": "/news/2026-05-comparison-therapies-alk-lung-cancer.html",
  "publishedAt": "2026-05-19T11:40:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted a head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. It is the first study to analyze two new drugs, lorlatinib and brigatinib, outside of clinical trials. The findings, just published in the journal Lung Cancer, could help patients and physicians make more informed decisions about treatment.",
  "title": "Comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions"
}